- Home
- PETS vs MGX Comparison
PETS vs MGX Comparison
Compare PETS & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- MGX
- Stock Information
- Founded
- PETS 1996
- MGX 2018
- Country
- PETS United States
- MGX United States
- Employees
- PETS N/A
- MGX N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- MGX
- Sector
- PETS Consumer Staples
- MGX
- Exchange
- PETS Nasdaq
- MGX NYSE
- Market Cap
- PETS 62.8M
- MGX 62.1M
- IPO Year
- PETS N/A
- MGX 2024
- Fundamental
- Price
- PETS $3.32
- MGX $1.58
- Analyst Decision
- PETS Sell
- MGX Strong Buy
- Analyst Count
- PETS 2
- MGX 4
- Target Price
- PETS $3.35
- MGX $13.00
- AVG Volume (30 Days)
- PETS 125.2K
- MGX 657.9K
- Earning Date
- PETS 08-05-2025
- MGX 08-13-2025
- Dividend Yield
- PETS N/A
- MGX N/A
- EPS Growth
- PETS N/A
- MGX N/A
- EPS
- PETS 0.02
- MGX N/A
- Revenue
- PETS $247,010,000.00
- MGX $45,263,000.00
- Revenue This Year
- PETS N/A
- MGX N/A
- Revenue Next Year
- PETS N/A
- MGX $11.75
- P/E Ratio
- PETS $195.73
- MGX N/A
- Revenue Growth
- PETS N/A
- MGX N/A
- 52 Week Low
- PETS $2.90
- MGX $1.23
- 52 Week High
- PETS $6.85
- MGX $5.50
- Technical
- Relative Strength Index (RSI)
- PETS 39.75
- MGX 51.92
- Support Level
- PETS $3.20
- MGX $1.41
- Resistance Level
- PETS $3.35
- MGX $1.59
- Average True Range (ATR)
- PETS 0.19
- MGX 0.12
- MACD
- PETS -0.06
- MGX 0.00
- Stochastic Oscillator
- PETS 16.52
- MGX 47.62
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.